# Cardiol Therapeutics Inc.: Form 40-F/A for the period ended Dec 31, 2021

- Company: [Cardiol Therapeutics Inc.](/companies/crdl.md) (CIK 1702123)
- Form: 40-F/A
- Filed: 2022-04-20
- Accepted by EDGAR: Apr 20, 2022, 16:49 ET
- Period: 2021-12-31
- Accession: 0001104659-22-047891
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1702123/000110465922047891/crdl-20211231x40fa.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1702123/000110465922047891/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2021-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 12 months, 2021-01-01 to 2021-12-31 | CAD 78.8k | ifrs-full:Revenue |
| Operating income | 12 months, 2021-01-01 to 2021-12-31 | −CAD 38.7m | ifrs-full:ProfitLossFromOperatingActivities |
| Income tax | 12 months, 2021-01-01 to 2021-12-31 | CAD 0 | ifrs-full:IncomeTaxExpenseContinuingOperations |
| Net income | 12 months, 2021-01-01 to 2021-12-31 | −CAD 31.6m | ifrs-full:ProfitLoss |
| Diluted EPS | 12 months, 2021-01-01 to 2021-12-31 | −CAD 0.73 | ifrs-full:DilutedEarningsLossPerShare |
| Basic EPS | 12 months, 2021-01-01 to 2021-12-31 | −CAD 0.73 | ifrs-full:BasicEarningsLossPerShare |
| Operating cash flow | 12 months, 2021-01-01 to 2021-12-31 | −CAD 23.6m | ifrs-full:CashFlowsFromUsedInOperatingActivities |
| Capital expenditure | 12 months, 2021-01-01 to 2021-12-31 | CAD 12.9k | ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities |
| Cash and equivalents | at 2021-12-31 | CAD 83.9m | ifrs-full:CashAndCashEquivalents |
| Current assets | at 2021-12-31 | CAD 87.1m | ifrs-full:CurrentAssets |
| Total assets | at 2021-12-31 | CAD 87.9m | ifrs-full:Assets |
| Current liabilities | at 2021-12-31 | CAD 11.6m | ifrs-full:CurrentLiabilities |
| Total liabilities | at 2021-12-31 | CAD 11.6m | ifrs-full:Liabilities |
| Shareholders' equity | at 2021-12-31 | CAD 76.2m | ifrs-full:Equity |
| Shares outstanding | at 2021-12-31 | 61,922,999 shares | dei:EntityCommonStockSharesOutstanding |

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1702123/000110465922047891/crdl-20211231x40fa.htm

Filed Apr 20, 2022.
Source: SEC EDGAR, the filing index for accession 0001104659-22-047891. Last ingested by Listed: Nov 3, 2026, 21:47 ET. No prices; not investment advice.